Summary
Global Markets Direct’s, ‘Humabs BioMed SA - Product Pipeline Review - 2016’, provides an overview of the Humabs BioMed SA’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Humabs BioMed SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Humabs BioMed SA
- The report provides overview of Humabs BioMed SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Humabs BioMed SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Humabs BioMed SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Humabs BioMed SA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Humabs BioMed SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Humabs BioMed SA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Humabs BioMed SA Snapshot 6
Humabs BioMed SA Overview 6
Key Information 6
Key Facts 6
Humabs BioMed SA - Research and Development Overview 7
Key Therapeutic Areas 7
Humabs BioMed SA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Humabs BioMed SA - Pipeline Products Glance 16
Humabs BioMed SA - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Humabs BioMed SA - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Humabs BioMed SA - Drug Profiles 20
Monoclonal Antibody for HCMV Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
FI-6 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
mAb-100 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
mAb-114 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody for Dengue 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for HBV Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for Influenza B Infections 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody for Rabies 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody for Staphylococcus Aureus Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MPE-8 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NVB-71.4 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody 1 for Undisclosed Indication 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody 2 for Undisclosed Indication 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody for Epstein-Barr Viral Infection 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody for Undisclosed Indication 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody for Viral Infections 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody for Zika Virus Infection 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Humabs BioMed SA - Pipeline Analysis 38
Humabs BioMed SA - Pipeline Products by Target 38
Humabs BioMed SA - Pipeline Products by Molecule Type 39
Humabs BioMed SA - Pipeline Products by Mechanism of Action 40
Humabs BioMed SA - Dormant Projects 41
Humabs BioMed SA - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44
List of Tables
Humabs BioMed SA, Key Information 6
Humabs BioMed SA, Key Facts 6
Humabs BioMed SA - Pipeline by Indication, 2016 8
Humabs BioMed SA - Pipeline by Stage of Development, 2016 10
Humabs BioMed SA - Monotherapy Products in Pipeline, 2016 11
Humabs BioMed SA - Partnered Products in Pipeline, 2016 12
Humabs BioMed SA - Partnered Products/ Combination Treatment Modalities, 2016 13
Humabs BioMed SA - Out-Licensed Products in Pipeline, 2016 14
Humabs BioMed SA - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Humabs BioMed SA - Phase II, 2016 16
Humabs BioMed SA - Phase I, 2016 17
Humabs BioMed SA - Preclinical, 2016 18
Humabs BioMed SA - Discovery, 2016 19
Humabs BioMed SA - Pipeline by Target, 2016 38
Humabs BioMed SA - Pipeline by Molecule Type, 2016 39
Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016 40
Humabs BioMed SA - Dormant Developmental Projects,2016 41
List of Figures
Humabs BioMed SA - Pipeline by Top 10 Indication, 2016 8
Humabs BioMed SA - Pipeline by Stage of Development, 2016 10
Humabs BioMed SA - Monotherapy Products in Pipeline, 2016 11
Humabs BioMed SA - Pipeline by Target, 2016 38
Humabs BioMed SA - Pipeline by Molecule Type, 2016 39
Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016 40
